Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Tecentriq (atezolizumab) is a PDL-1 inhibitor monoclonal antibody, It is approved by EMA for the treatment of patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC).
Lead Product(s): Atezolizumab
Therapeutic Area: Oncology Product Name: Tecentriq
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: F. Hoffmann-La Roche
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
The collaboration will provide Acumen access to Halozyme's ENHANZE® drug delivery technology, based on a recombinant human hyaluronidase PH20 enzyme (rHuPH20), for the development of a subcutaneous formulation of ACU193, the first clinical-stage AβO-targeting antibody.
Lead Product(s): ACU193
Therapeutic Area: Neurology Product Name: ACU193
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Acumen Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 06, 2023
Details:
Tecentriq (atezolizumab) is a monoclonal antibody, binds with PD-L1, which is expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, drug may enable the activation of T-cells.
Lead Product(s): Atezolizumab
Therapeutic Area: Oncology Product Name: Tecentriq
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: F. Hoffmann-La Roche
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2023
Details:
VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection with ENHANZE for subcutaneous (SC) use for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.
Lead Product(s): Efgartigimod Alfa,Hyaluronidase-qvfc
Therapeutic Area: Immunology Product Name: Vyvgart Hytrulo
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Argenx
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
TLANDO (testosterone undecanoate) is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.
Lead Product(s): Testosterone Undecanoate
Therapeutic Area: Endocrinology Product Name: Tlando
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 07, 2022
Details:
Halozyme and Antares will create a drug delivery and specialty product company. The Antares business consists of a best-in-class, auto injector and ENHANZE platform that offers broad licensing opportunity, with 3 commercial products including Tlando (testosterone undecanoate).
Lead Product(s): Testosterone Undecanoate
Therapeutic Area: Endocrinology Product Name: Tlando
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Antares Pharma
Deal Size: $960.0 million Upfront Cash: $960.0 million
Deal Type: Acquisition May 24, 2022
Details:
TLANDO® is an oral treatment for testosterone replacement therapy indicated for conditions associated with a deficiency or absence of endogenous testosterone in adult males.
Lead Product(s): Testosterone Undecanoate
Therapeutic Area: Endocrinology Product Name: Tlando
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Lipocine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2022
Details:
The combination of Halozyme and Antares will create a drug delivery and specialty product company. The Antares business consists of a best-in-class, auto injector and ENHANZE platform that offers broad licensing opportunity, with 3 commercial products including Tlando.
Lead Product(s): Testosterone Undecanoate
Therapeutic Area: Endocrinology Product Name: Tlando
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Antares Pharma
Deal Size: $960.0 million Upfront Cash: $960.0 million
Deal Type: Acquisition April 13, 2022
Details:
TLANDO ® (testosterone undecanoate), an oral treatment for testosterone replacement therapy (“TRT”) indicated for conditions associated with a deficiency or absence of endogenous testosterone, or hypogonadism in adult males.
Lead Product(s): Testosterone Undecanoate
Therapeutic Area: Endocrinology Product Name: Tlando
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Lipocine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 29, 2022
Details:
Chugai represents Halozyme's twelfth global collaboration and license partner for the ENHANZE® technology. Halozyme's proprietary ENHANZE® drug-delivery technology is based on its patented recombinant human hyaluronidase enzyme (rHuPH20).
Lead Product(s): Recombinant Human Hyaluronidase PH20 Enzyme
Therapeutic Area: Technology Product Name: rHuPH20
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Chugai Pharmaceutical
Deal Size: $185.0 million Upfront Cash: $25.0 million
Deal Type: Collaboration March 24, 2022